Every 10-Q that Precision BioSciences, Inc. (DTIL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DTIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DTIL filings page.
Precision BioSciences is a clinical-stage gene editing company developing in vivo therapies using its proprietary ARCUS platform, led by HBV program PBGENE‑HBV and DMD program PBGENE‑DMD. In the ELIMINATE‑B trial, liver biopsies showed about a 1‑log reduction in cccDNA‑derived transcripts after PBGENE‑HBV dosing, with less than 1% of cccDNA remaining in one patient and cumulative effects with repeat dosing. pgRNA became durably undetectable in all patients who had detectable pgRNA at baseline, with sustained S‑antigen declines and no dose‑limiting toxicities reported across 16 patients.
For the six months ended June 30, 2026, the company reported $10.8 million of revenue, primarily from a $7.5 million milestone under the TG Therapeutics license and a $4.0 million agriculture milestone, versus less than $0.1 million a year earlier. Research and development expenses were $25.5 million and general and administrative expenses $13.6 million, yielding an operating loss of $28.2 million. A large non‑cash loss from remeasurement of warrant liabilities and other fair value items drove total net loss to $51.1 million.
Cash, cash equivalents and restricted cash totaled $112.4 million at June 30, 2026, including $22.5 million held as security for a term loan maturing in 2029. Management states that existing cash, operating discipline and access to an at‑the‑market equity facility are expected to fund operations through 2028.
Precision BioSciences reported Q1 2026 results showing higher revenue but continued losses as it advances its gene-editing pipeline. Revenue rose to $10.8 million from collaboration milestones and a legacy agriculture agreement, while the company recorded a net loss of $18.4 million, or $0.75 per share.
Research and development expenses were $13.1 million and general and administrative expenses were $6.8 million, reflecting investment in lead programs PBGENE‑HBV and PBGENE‑DMD and lower overhead versus last year. Cash, cash equivalents and restricted cash totaled $125.8 million, and management believes this can fund operations through 2028, assuming access to its at‑the‑market equity facility.
Clinically, PBGENE‑HBV continued enrollment in the ELIMINATE‑B trial with 16 patients treated and more data expected at hepatology conferences in 2026. PBGENE‑DMD received FDA Fast Track designation, cleared its IND and began enrolling patients in the Phase 1/2 FUNCTION‑DMD trial.
Precision BioSciences (DTIL) filed its Q3 2025 10-Q, reporting continued investment in ARCUS gene editing programs and a wider net loss. Quarterly revenue was $13 thousand, reflecting lower billable work under the Novartis collaboration. Operating loss was $20.7 million and net loss was $21.8 million. Cash and cash equivalents were $44.9 million, with restricted cash of $26.3 million; total cash, cash equivalents and restricted cash were $71.2 million as of September 30, 2025.
The balance sheet shows total liabilities of $76.9 million, including a $22.5 million term loan and $26.2 million in deferred revenue, and stockholders’ equity of $16.6 million. A warrant liability was $4.0 million. Shares outstanding were 12,082,665 as of September 30, 2025, and 13,256,751 as of October 29, 2025.
PBGENE-HBV advanced with Cohort 3 dosing in the ELIMINATE-B trial, while PBGENE-DMD moved toward an anticipated U.S. IND filing by year-end 2025 after receiving Rare Pediatric Disease and Orphan Drug designations. Subsequent events included an $8.0 million milestone from Imugene on October 31, 2025 (paid as $3.0 million cash and $5.0 million stock) and Novartis’ notice to terminate the collaboration effective January 30, 2026.